Pipeline Progress at Synergy Pharma - Analyst Blog
November 04 2013 - 5:00PM
Zacks
Synergy Pharmaceuticals
Inc. (SGYP) currently has no approved products. The
company has progressed well with its pipeline in the last few
quarters. SP-333 is one of the important candidates in Synergy
Pharma’s pipeline, being developed for the treatment of
inflammatory bowel diseases (IBD), like ulcerative colitis and
opioid-induced constipation (OIC).
Last week, Synergy Pharma initiated a phase II study on SP-333. The
study will evaluate the safety and efficacy of SP-333 in adults
suffering from OIC. The phase II study (dose-ranging study) will be
evaluating a 4-week regimen of SP-333 in patients who have been
taking opioid analgesics for chronic, non-cancer pain for a minimum
of three months.
Synergy Pharma intends to enrol 260 patients with OIC who have less
than 3 spontaneous bowel movements (SBMs) per week and have
experienced constipation-related symptoms. The main objective of
the study is to evaluate the mean change from baseline in the
number of SBMs during the final week of the treatment period.
We note that earlier in the year Synergy Pharma successfully
completed a phase I placebo-controlled, dose-escalating,
multiple-dose study on SP-333 in patients with IBD.
Another interesting candidate at Synergy Pharma is plecanatide.
Plecanatide is currently in a phase IIb study for the treatment of
patients suffering from irritable bowel syndrome with constipation
(IBS-C). Synergy Pharma expects to enrol the last patient for the
study by year end and release top-line data from this study in the
first quarter of 2014.
We expect investor focus to remain on updates regarding the
development of the company’s pipeline. The successful development
and commercialization of the candidates would be a major positive
for Synergy Pharma. The constipation market currently has products
like Ironwood Pharmaceuticals/Forest
Laboratories’ (IRWD)/ (FRX) Linzess.
Synergy Pharma currently carries a Zacks Rank #3 (Hold). Right now,
Actelion Ltd. (ALIOF) looks attractive with a
Zacks Rank #1 (Strong Buy).
ACTELION LTD (ALIOF): Get Free Report
FOREST LABS A (FRX): Free Stock Analysis Report
IRONWOOD PHARMA (IRWD): Free Stock Analysis Report
SYNERGY PHARMAC (SGYP): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jul 2023 to Jul 2024